STHanMD Profile Banner
Sheila Angeles-Han Profile
Sheila Angeles-Han

@STHanMD

Followers
904
Following
7K
Media
68
Statuses
1K

Peds rheumatologist. Mother. Wife. 🏖 & 🐶 lover. 👁🦵🏼researcher ➡️ #uveitis, #pedsrheum, #jia @CincyChildrens Views expressed are my own. 🇵🇭🇺🇸

Cincinnati, OH
Joined March 2018
Don't wanna be here? Send us removal request.
@STHanMD
Sheila Angeles-Han
8 months
Our new📝 reports on biomarkers in #tearfluid 💧of 👧🏻🧒🏻 with #jia based on #uveitis diagnosis. Several are associated with the RPE & blood retinal barrier, and previously detected in aqueous humor. #pedsrheum @GrantSchulert .
Tweet card summary image
tandfonline.com
Uveitis is an inflammatory ocular disease secondary to disruption of the retinal pigmented epithelium (RPE) and blood retinal barrier (BRB). Known clinical factors do not accurately predict uveitis...
0
4
17
@STHanMD
Sheila Angeles-Han
9 months
Calling all early-career researchers! The @CureArthritis 2025 grants are open for applications on Nov 4. From Psoriatic Arthritis to Pediatric Rheumatology, these grants fund game-changing research. Apply today: #ArthritisResearch #Rheumatology #pedsrheum.
Tweet card summary image
curearthritis.org
The Arthritis National Research Foundation provides arthritis research grants for research scientists. If you're looking for arthritis research grants see the options here.
0
8
16
@STHanMD
Sheila Angeles-Han
10 months
Honored to join the Scientific Advisory Board of Arthritis National Research Foundation! . @CureArthritis Mission: Provide initial research funding to brilliant, investigative scientists with new ideas to cure arthritis and related autoimmune diseases. #jia #pedsrheum #uveitis.
2
3
18
@STHanMD
Sheila Angeles-Han
11 months
We newly report in 8👧🏻🧒🏻 w/ Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. ➡️Systemic treatment w/ MTX, IFX, TCZ.➡️ 👁️ outcomes. W/ Arjun Sood @GrantSchulert .#ADNIV #uveitis #pedsrheum. ➡️
Tweet card summary image
tandfonline.com
Autosomal dominant neovascular inflammatory vitreoretinopathy (NIV), formerly called “ADNIV,” is a rare autoinflammatory condition mainly of adulthood caused by mutations in calcium-activated calpa...
0
1
10
@STHanMD
Sheila Angeles-Han
11 months
RT @PRheumdoc: Results of our recent study on Tofacitinib in JIA.@NetworkPrcsg @jaymehtamd @GrantSchulert @STHanMD @HermineBrunner0 @LauraL….
0
3
0
@STHanMD
Sheila Angeles-Han
1 year
We report that 84% of 110 👦🏻👧🏻 w/ tubulointerstitial nephritis + uveitis syndrome needed IMT (45% biologics). Younger age, male sex and ⬆️ uveitis grade were associated with use of 2 or more IMT.
Tweet card summary image
nature.com
Eye - Clinical outcomes in paediatric tubulointerstitial nephritis and uveitis syndrome (TINU)
0
0
2
@STHanMD
Sheila Angeles-Han
1 year
RT @GrantSchulert: Congratulations to all these amazing new @carrainc grant awardees including my @CincyChildrens colleagues @STHanMD Dani….
0
3
0
@STHanMD
Sheila Angeles-Han
1 year
We report novel UWFFA & OCT findings in children with autosomal dominant neovascular inflammatory vitreoretinopathy-ADNIV & steroid response. EARLY CAPN5 testing, screening for #uveitis & retinal vasculitis, & tx may alter the natural history #pedsrheum .
0
3
8
@STHanMD
Sheila Angeles-Han
1 year
A simplified approach to uveitis screening when JIA category and ANA status are unknown. Young children with JIA who are recently diagnosed are at greatest risk. #pedsrheum #uveitis #jia @AntonJordi68 @lolaeyedoc @uveitisharry.
@BMJ_Ophth
Ophthalmology at BMJ
1 year
The Multinational Interdisciplinary Working Group for Uveitis in Childhood experts developed a simplified and practical #uveitis screening guide for patients with juvenile idiopathic arthritis (JIA) associated uveitis, read here: #rheum #eyes #pediatrics
Tweet media one
0
3
18
@STHanMD
Sheila Angeles-Han
1 year
RT @USSONAR_Rh: .@Patricia_VegaF teaching elbow ultrasound with the newest Clarius hand held. Thanks @clariusmhealth for your support of ou….
0
7
0
@STHanMD
Sheila Angeles-Han
2 years
RT @EdmundTsuiMD: Excited for our session in the @ARVOinfo Biomarkers Conference: OCT-based quantification of anterior chamber inflammation….
0
4
0
@STHanMD
Sheila Angeles-Han
2 years
RT @NEIDirector: From @PittTweet @PittPubHealth @MassEyeAndEar @HMSEye @JohnKempen3 and collaborators:. No evidence of excess risk of cance….
0
6
0
@STHanMD
Sheila Angeles-Han
2 years
Excited and honored to be selected for this amazing opportunity - AMP AIM Team Science LSP in Women’s Health! @OMRF @NIH_NIAMS @NIH_ORWH @NIHDataScience @CincyChildrens @NatEyeInstitute #uveitis #jia #pedsrheum.
@NIH_NIAMS
NIAMS
2 years
In collaboration with @NIH_ORWH and @NIHDataScience, NIAMS is excited to announce the inaugural cohort of the Team Science Leadership Scholars Program in Women’s Health. Read our recently published Director’s letter to learn more about the program:
10
4
23
@STHanMD
Sheila Angeles-Han
2 years
RT @carrainc: Do you or your child have #juvenilearthritis and are you 18 or older? If yes, please complete this brief survey https://t.co/….
0
10
0
@STHanMD
Sheila Angeles-Han
2 years
RT @WileyHealth: Updated pediatric #uveitis recommendations advise on expanded treatment options. Read for free the May #Arthritis Care &….
0
5
0
@STHanMD
Sheila Angeles-Han
2 years
RT @emarchiolo: The Foundation for Research in Rheumatology (FOREUM) and @RheumResearch are jointly issuing a call for apps highlighting fu….
0
11
0
@STHanMD
Sheila Angeles-Han
2 years
RT @ericdeinmd: @jeffsparks .New indications for autoimmune medications and new recent pediatric indications.#ACRX23 #SOTA @RheumNow https:….
0
2
0
@STHanMD
Sheila Angeles-Han
2 years
RT @ericdeinmd: HCQ safety:.<5mg/kg/d leads to flare risk.>5mg/kg leads to higher 👀 risk. 1/5 with retinal toxicity at 15 years for >6 mg/k….
0
16
0
@STHanMD
Sheila Angeles-Han
2 years
RT @GrantSchulert: Finally! Excited to see this in print:. Efficacy and safety of emapalumab in macrophage activation syndrome | Annals of….
0
18
0
@STHanMD
Sheila Angeles-Han
2 years
RT @rheumdoctor: How to approach refractory #uveitis? #PRSYM23
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
13
0